Add to Cart
The kit was used for qualitative detection of ncov Ag in 2019 and
was extracted from human saliva / sputum samples.
2019 ncov is a new type β- COV. Can cause viral pneumonia. The main
clinical symptoms are fever, fatigue and dry cough. Some patients
have nasal congestion, runny nose, sore throat, diarrhea and other
symptoms. Fatal cases often develop dyspnea and / or hypoxemia
after one week. Severe cases are acute dyspnea syndrome, septic
shock, uncorrectable metabolic acidosis and coagulation
dysfunction.
The product uses side flow immunoassay to detect ncov Ag in 2019 in
saliva / sputum samples of suspected patients. In the acute phase
of infection, antigens are usually detected in saliva and sputum
samples. The positive results showed the presence of virus antigen,
but the clinical correlation between patient history and other
diagnostic information was also a necessary condition to determine
the infection. Positive results cannot exclude bacterial infection
or co infection with other viruses. The pathogen detected may not
be the exact cause of the disease. Negative results cannot exclude
the infection of ncov in 2019 and cannot only be used as the basis
for treatment or patient management decisions (including infection
management decisions). If it is negative, the patient's recent
contact force, medical history, clinical signs consistent with ncov
in 2019 and the presence or absence of symptoms will be finally
judged. If necessary, it will be confirmed by nucleic acid
analysis.
The kit consists of test card, sample buffer and cotton swab.
Test card: it is composed of aluminum foil bag, desiccant, test
tape and plastic card. The test tape consists of absorption paper,
nitrocellulose film, sample pad, adhesive pad and rubber plate. The
coating of nitrocellulose membrane t production line (test
production line) is 2019 ncov AB, and the coating of production
line C (quality management production line) is chlorine reverse gum
PVC. The binding plate contains the binding plate labeled 2019 ncov
ab.
Sample buffer: phosphate, sodium azide, etc
It shall be stored at 2 ℃ ~ 30 ℃, and the validity period is
tentatively 18 months.
The validity period of aluminum foil package is 1 hour after
opening the package.
Production batch No.: please refer to the label for details.
Validity period: please refer to the label for details.
(1) Collect saliva samples: do not drink water, drink water, smoke
or contain chewing gum 30 minutes before collecting saliva samples.
Put the root of the tongue on the root of the tongue, put the
sterilized disposable cotton swab under the root of the tongue for
more than 10 seconds, completely soak it in saliva and rotate it
for more than 5 times. (see Figure 1)
Note: if saliva samples are not collected correctly, stomach
negative results may occur.
Figure 1 Methodsfor saliva sample collection
Figure 2 Methods for sputum sample collection
(2) Collect sputum samples: after washing with clean water, spit
into the sample bag and wipe the sample with a disposable sterile
cotton swab. (see Figure 2)
(3) Sample treatment: the collected sample shall be treated with
the sample buffer provided by the kit as soon as possible (if it
cannot be treated immediately, the sample shall be stored in a dry,
sterilized and sealed container for future detection). 2 ℃ ~ 8 ℃
shall not exceed 24h, and it shall be stored at - 70 ℃ for a long
time (but avoid repeated freezing and thawing).
Please read the guide carefully before testing. Please restore all
reagents to room temperature before testing. The test must be
carried out at room temperature.
1. Sample processing (see Figure 3)
(1) Take the cotton swab for examination and put it into the buffer
solution of the examination body. Rotate it near the inner wall for
about 10 times to make the examination body dissolve in the
solution as much as possible.
(2) Twist the tip of the cotton swab along the tube wall to make
the liquid enter the tube to the maximum extent, and then extract
and discard the cotton swab.
(3) Overlay buffer.
Figure 3 Sample processing
Figure 4 Test procedure
2. Test procedure (see Figure 4)
(1) Remove the test card.
(2) Extract 2 drops (about 80%) of the treated sample μ 50) put it
into the sampling hole of the test card and start the timer.
Place the card at room temperature for 15 minutes and read the
results. After 20 minutes, the result failed.
Analysis of test card (see Figure 5):
1. Invalid result: the quality management line (line C) does not
respond, the line is invalid, and it needs to be retested.
2. Negative results: quality management line (line C), red ribbon,
coloring.
3. Positive result: the two red bands of test line (t line) and
quality management line (C line) are colored.
Figure 5 Interpretation of test results
1. This product is a qualitative test and is only used for in vitro
auxiliary diagnosis.
2. The product is suitable for saliva and sputum samples. Other
sample types may be incorrect or have wrong results.
3. If the patient does not have sputum sample, nasopharynx cotton
swab sample should be used for examination.
4. Ensure that an appropriate number of samples are added for
testing. If there are too many or too few samples, incorrect
results may be produced.
5. The test results of the reagent can only be used for clinical
reference, not the only basis for clinical diagnosis and treatment.
The final diagnosis of the disease can only be made after a
comprehensive evaluation of all clinical and laboratory results.
1. Detection limit: in this study, inactive sars-cov-2 virus medium
was used, and the minimum detection limit was 6 × 102TCID50/mL.
2. Enterprise reference materials are used for testing, and the
results must meet the requirements of enterprise reference
materials.
2.1 qualification rate of positive control samples: p1-p5 of
positive control samples of enterprises are tested as positive.
2.2 qualification proportion of negative control samples: the
negative control samples n1-n10 of the enterprise have been tested
as negative.
2.3 detection limit: the minimum detection limit of the detection
enterprise is L1-L3, L1 is negative, L2 and L3 are positive.
2.4 reproducibility: the repeated reference substances J1 and J2 of
the enterprise are detected and positive for 10 times respectively.
3. Cross reaction: according to the specified concentration, add
the following concentrations of microorganisms and viruses to the
sample to evaluate the potential interference to the 2019 ncov Ag
test project. The results showed that there was no cross reaction
and was not disturbed by a variety of microorganisms and viruses.
SN | Microorganisms | Concentration | Cross reaction |
1 | Coronavirus (HKU1, OC43, NL63 and 229E) | 1.0×105TCID50/mL | No |
2 | Influenza A H1N1 (novel influenza A H1N1 virus (2009), seasonal H1N1 influenza virus), H3N2, H5N1, H7N9 | 1.0×105TCID50/mL | No |
3 | Influenza B (Yamagata strain, Victoria strain) | 2.5×105TCID50/mL | No |
4 | Respiratory syncytial virus | 2.8×105TCID50/mL | No |
5 | Group A, B, C of rhinovirus | 2.0×105TCID50/mL | No |
6 | Type 1, 2, 3, 4, 5, 7, 55 of adenovirus | 2.0×105TCID50/mL | No |
7 | Group A, B, C and D of enterovirus | 2.0×105TCID50/mL | No |
8 | EB virus | 2.0×105TCID50/mL | No |
9 | Measles virus | 2.0×105TCID50/mL | No |
10 | Human cytomegalovirus | 2.0×105TCID50/mL | No |
11 | Rotavirus | 2.0×105TCID50/mL | No |
12 | Norovirus | 2.0×105TCID50/mL | No |
13 | Mumps virus | 2.0×105TCID50/mL | No |
14 | Varicella-zoster virus | 2.0×105TCID50/mL | No |
15 | Mycoplasma pneumoniae | 1.0×106CFU/mL | No |
16 | Legionella pneumophila | 1.0×106CFU/mL | No |
17 | Haemophilus influenzae | 1.0×106CFU/mL | No |
18 | Streptococcus pyogenes (group A) | 1.0×106CFU/mL | No |
19 | Streptococcus pneumoniae | 1.0×106CFU/mL | No |
20 | Escherichia Coli | 1.0×106CFU/mL | No |
21 | Pseudomonas aeruginosa | 1.0×106CFU/mL | No |
22 | Neisseria meningitidis | 1.0×106CFU/mL | No |
23 | Candida albicans | 1.0×106CFU/mL | No |
24 | Staphylococcus aureus | 1.0×106CFU/mL | No |
4.Interfering substances: in the 2019 ncov Ag test project, in order to evaluate potential interference, the following concentrations of drugs have been added to the samples with specified concentrations. The results showed that all types of drugs did not affect the test results.
Interfering substances | Concentration | Interfering substances | Concentration |
Mucoprotein | 1mg/mL | Ribavirin | 0.4mg/mL |
Whole Blood | 1% | Fluticasone | 0.5mg/mL |
Oxymetazoline | 10mg/mL | Dexamethasone | 5 mg/mL |
Histamine hydrochloride | 10mg/mL | Triamcinolone acetonide | 5 mg/mL |
Tobramycin | 1mg/mL | Levofloxacin | 0.2 mg/mL |
Oseltamivir | 1mg/mL | Azithromycin | 0.1 mg/mL |
Zanamivir | 1mg/mL | Ceftriaxone | 0.4 mg/mL |
Arbidol | 0.5mg/mL | Meropenem | 0.2 mg/mL |
5. Hooke effect: inactive 2019 ncov culture detected 1.0 × High
concentration Hooke effect of 106tcid50 / ml.
The kit was used for qualitative detection of ncov Ag in 2019 and
was extracted from human saliva / sputum samples.
2019 ncov is a new type β- COV. Can cause viral pneumonia. The main
clinical symptoms are fever, fatigue, dry cough and so on. Some
patients have nasal congestion, runny nose, sore throat, diarrhea
and other symptoms. Fatal cases usually develop dyspnea and / or
hypoxemia after one week. In severe cases, acute dyspnea syndrome,
septic shock, uncorrectable metabolic acidosis and coagulation
dysfunction develop rapidly.
The product uses side flow immunoassay to detect 2019 ncov Ag in
saliva / sputum samples of suspected patients. In the acute phase
of infection, antigens are usually detected in saliva and sputum
samples. The positive results showed the presence of virus antigen,
but the clinical correlation between patient history and other
diagnostic information was also a necessary condition to determine
the infection. Positive results cannot exclude bacterial infection
or co infection with other viruses. The pathogen detected may not
be the exact cause of the disease. The possibility of infection
management decision (ncov) can not be excluded as the basis of
infection management decision in 2019. If it is negative, the final
contact force and history of the patient will be determined,
together with the clinical signs and symptoms of COVID-19 infection
(covid - 19) in 2019.
6. Clinical study: use RT-PCR detection reagent as comparison
reagent to detect saliva and sputum samples respectively. We
selected 120 positive samples and 120 negative samples (RT-PCR),
the size of each sample, and then detected it with Zhongxiu
reagent. The result is this.
guide
1. This product is only used for in vitro diagnosis.
2. This product is disposable and cannot be reused.
3. Please read the experiment guide carefully before starting and
carry out the experiment according to the reagent guide.
4. Avoid conducting experiments under harsh environmental
conditions (including disinfectant, sodium hypochlorite, acid
alkali, acetaldehyde and other high concentration corrosive gases,
dust and other environments). The laboratory should be disinfected
after the experiment.
5. All samples and used reagents should be considered as potential
infectious substances and treated in accordance with local
regulations.
6. The reagent must be used within the validity period indicated on
the outer package. The test card shall be taken out of the aluminum
foil bag to prevent moisture, and then used as soon as possible.
Do not re-use | Store at 2℃~30℃ | ||
Consult instructions for use | In vitro diagnostic medical device | ||
Batch code | Use-by date | ||
Keep dry | Keep away from sunlight | ||
Authorized representative in the European Community | Manufacturer |
ZHONGXIU SCIENCE AND TECHNOLOGY CO.,LTD
Dingluan industrial zone ,Changyuan City,453400,P.R.CHINA
Tel:+86-371-55016575
Email:zosbio@zosbio.com
Web:www.zosbio.com
SUNGO Europe B.V.
Olympisch Stadion 24, 1076DE Amsterdam, Netherlands
5 mg/mL |